Why Organon Is A Top Pick For Income Investors
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
High-Yield Healthcare: 3 Stocks With Strong Dividends
When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income.
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Q4 Earnings and Revenues Beat Estimates
Organon (OGN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago.
Why Organon (OGN) Dipped More Than Broader Market Today
Organon (OGN) concluded the recent trading session at $14.62, signifying a -1.81% move from its prior day's close.
Organon (OGN) Rises Higher Than Market: Key Facts
The latest trading day saw Organon (OGN) settling at $15.97, representing a +0.82% change from its previous close.
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know
Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day.
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session.
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield.
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)
Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
